Literature DB >> 22280806

Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma.

Jeffrey Kit Loong Tuan1, Tam Cam Ha, Whee Sze Ong, Tian Rui Siow, Ivan Weng Keong Tham, Swee Peng Yap, Terence Wee Kiat Tan, Eu Tiong Chua, Kam Weng Fong, Joseph Tien Seng Wee.   

Abstract

BACKGROUND AND
PURPOSE: We sought to evaluate the nature and frequency of late toxicities in a cohort of nasopharyngeal cancer (NPC) patients treated with conventional radiotherapy alone. METHODS AND MATERIALS: Seven-hundred and ninety-six consecutive NPC patients treated using conventional radiotherapy at a single center from 1992 to 1995 were retrospectively analyzed. Patients with histology proven, completely staged, Stage I-IVB World Health Organization Type I-III NPC and completed radical radiotherapy were included. Patients with incomplete staging investigations, distant metastases at diagnosis, previous treatment, and incomplete radiotherapy were excluded. Radiotherapy-related complications were categorized using the RTOG Late Radiation Morbidity Scoring Criteria.
RESULTS: Median follow-up was 7.2 years. The 5-year overall survival and disease free survival were 69% and 56%, respectively, and the corresponding 10-year rates were 52% and 44%. Among 771 patients with at least 3 months of follow-up post treatment, 565 (73%) developed RT-related complications. Diagnosed neurological complications were cranial nerve palsies (n=70; 9%), temporal lobe necrosis (n=37; 5%), Lhermitte's syndrome (n=7; 1%), and brachial plexopathy (n=2; 0.3%). Non-neurological complications included xerostomia (n=353; 46%), neck fibrosis (n=169; 22%), hypo-pituitarism (n=48; 6%), hearing loss (n=120; 16%), dysphagia (n=116; 15%), otorrhea (n=101; 13%), tinnitus (n=94; 12%), permanent tube feeding (n=61; 8%), trismus (n=45; 6%), second malignancies within treatment field (n=17; 2%), and osteo-radionecrosis (n=13; 2%).
CONCLUSIONS: While radiotherapy is curative in NPC, many patients suffer significant late treatment morbidities with conventional radiotherapy techniques.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22280806     DOI: 10.1016/j.radonc.2011.12.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  30 in total

1.  SmartArc-based volumetric modulated arc therapy can improve the middle ear, vestibule and cochlea sparing for locoregionally advanced nasopharyngeal carcinoma: a dosimetric comparison with step-and-shoot intensity-modulated radiotherapy.

Authors:  J Gao; T-L Qian; C-Z Tao; Y-H Zhang; Y Zhou; J Yang; J He; R Wang; P-J Zhou
Journal:  Br J Radiol       Date:  2015-06-25       Impact factor: 3.039

2.  A simple technique for intubating the mouth during OGD in patients with previous neck radiation.

Authors:  Christina E Buckley; Akbar Amin Achakzai; Deirdre O'Hanlon
Journal:  BMJ Case Rep       Date:  2014-05-20

3.  The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.

Authors:  J J Yang; J Y S Lim; J Huang; J Bass; J Wu; C Wang; J Fang; E Stewart; E H Harstead; S E; G W Robinson; W E Evans; A Pappo; J Zuo; M V Relling; A Onar-Thomas; A Gajjar; C F Stewart
Journal:  Clin Pharmacol Ther       Date:  2013-06-11       Impact factor: 6.875

4.  Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer.

Authors:  Yanqun Dong; John A Ridge; Tianyu Li; Miriam N Lango; Thomas M Churilla; Jessica R Bauman; Thomas J Galloway
Journal:  Oral Oncol       Date:  2017-06-23       Impact factor: 5.337

5.  MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.

Authors:  Xiaoqin Fan; Yujie Wang; Jian Song; Hanwei Wu; Ming Yang; Lu Lu; Xin Weng; Lusha Liu; Guohui Nie
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

6.  Clinical observation and quality of life in terms of nasal sinusitis after radiotherapy for nasopharyngeal carcinoma: long-term results from different nasal irrigation techniques.

Authors:  H-H Luo; Z-C Fu; H-H Cheng; S-G Liao; D-S Li; L-P Cheng
Journal:  Br J Radiol       Date:  2014-05-12       Impact factor: 3.039

7.  Factors influencing the incidence of sinusitis in nasopharyngeal carcinoma patients after intensity-modulated radiation therapy.

Authors:  Yan-xia Su; Lan-ping Liu; Lei Li; Xu Li; Xiu-juan Cao; Wei Dong; Xin-hua Yang; Jin Xu; Shui Yu; Jun-fang Hao
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12       Impact factor: 2.503

8.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiaoshuang Niu; Chaosu Hu; Lin Kong
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-24       Impact factor: 4.553

9.  The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance.

Authors:  Rajamanickam Baskar; Swee Peng Yap; Kevin Lee Min Chua; Koji Itahana
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

10.  Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area.

Authors:  J Boustani; A Ruffier; A Moya-Plana; Y Tao; F Nguyen; C Even; C Berthold; O Casiraghi; S Temam; P Blanchard
Journal:  Strahlenther Onkol       Date:  2020-06-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.